Mistletoe Therapy in Oncology: A Holistic Approach to Cancer Care
Mistletoe therapy, rooted in anthroposophic medicine, has emerged as a complementary treatment in oncology, offering supportive benefits for cancer patients. Derived from the Viscum album plant, mistletoe extract is widely used in Europe—especially in Germany, where ABNOBA GmbH, a leading research-based pharmaceutical manufacturer, produces standardized mistletoe preparations. Now, ABNOBA India is extending this holistic approach to the Indian healthcare landscape.
Mistletoe therapy is primarily used to enhance quality of life, reduce chemotherapy side effects, and stimulate the immune system. Administered via subcutaneous injections, it helps patients better tolerate conventional treatments such as radiation and chemotherapy by mitigating fatigue, improving appetite, and stabilizing emotional well-being. It also encourages the body's self-healing capacity, an essential component in integrative cancer care.
Multiple clinical studies have demonstrated mistletoe’s potential in improving survival and reducing tumor-related symptoms, especially in breast, colorectal, and lung cancers. While not a replacement for conventional therapies, it acts as a valuable adjunct, especially for patients seeking a more comprehensive, patient-centered approach to care.
ABNOBA GmbH’s commitment to scientific rigor ensures high-quality, evidence-based formulations. With the launch of ABNOBA India, this integrative therapy becomes accessible to Indian oncologists and patients who seek safe, researched-based complementary solutions.
As awareness of integrative oncology grows, mistletoe therapy presents a promising avenue—one that bridges traditional wisdom and modern science for more compassionate cancer care.
Comments
Post a Comment